In 2014, the results of the randomized clinical trial phase III PROFILE 1014, comparing the efficacy of the first-generation ALK inhibitor crizotinib with pemetrexed and platinum-based chemotherapy as a first-line treatment for patients with metastatic ALK-positive NSCLC, were reported. This evidence concerns the gene ALK and non-small cell lung carcinoma.